Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. Thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.
Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. ICNB provides rapid and precise incision analgesia in the early postoperative period, effectively blocking the transmission of peripheral nociceptive stimuli to the central nervous system. tegileridine PCIA, on the other hand, enhances the function of the endogenous descending pain suppression system through its central G protein pathway activation, covering the pain period after the effect of ICNB wears off and components such as visceral referred pain. At the same time, it can effectively reduce side effects such as respiratory depression and nausea/vomiting, thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
118
Administer 0.015 mg/kg (maximum 1mg) of tegileridine intravenously 40 minutes before the end of surgery, followed by the connection of a tegileridine patient-controlled intravenous analgesia (PCIA)
Before closing the chest, the thoracic surgeon injected 3mL of 0.4% ropivacaine into the 4th, 5th, 6th and 7th intercostal spaces through thoracoscopy for intercostal nerve block.
Administer 0.15 μg/kg (maximum 10 μg) of sufentanil intravenously 40 minutes before the end of surgery, followed by the connection of a sufentanil patient-controlled intravenous analgesia (PCIA)
Tongji hospital
Wuhan, Hubei, China
RECRUITINGVAS (Visual Analog Scale) pain score
VAS pain score 0-10, the higher scores mean a worse outcome; Analgesic effect assessed during activity in the post-anesthesia care unit (PACU) and at 1, 6, 12, 24, 36, and 48 hours post-surgery
Time frame: 48 hours
total dosage of remedial analgesic drugs
The total consumption of remedial analgesic drugs within 48 hours post-surgery
Time frame: 48hours
PCIA-related parameters
Including total analgesic consumption, number of effective presses, and total number of presses
Time frame: 48 hours
Incidence of opioid-related adverse events (ORAEs)
Including Respiratory depression (defined as respiratory rate \< 8 breaths/min or SpO₂ \< 90%); ② Postoperative nausea and vomiting (PONV); ③ Pruritus; ④ Dizziness; ⑤ Delayed recovery of gastrointestinal function, etc.
Time frame: 48 hours
The length of postoperative hospital stay
The length of postoperative hospital stay from the end of surgery to hospital discharge
Time frame: 10 days
The quality of sleep
AIS sleep scale was used to assess the quality of sleep
Time frame: 10 days
the number of rescue analgesic interventions
the number of rescue analgesic interventions within 48 hours post-surgery
Time frame: 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
overall patient satisfaction
overall patient satisfaction post-surgery
Time frame: 10 days